Antineoplastic Agents
"Antineoplastic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Substances that inhibit or prevent the proliferation of NEOPLASMS.
Descriptor ID |
D000970
|
MeSH Number(s) |
D27.505.954.248
|
Concept/Terms |
Antineoplastic Agents- Antineoplastic Agents
- Agents, Antineoplastic
- Antineoplastic Drugs
- Drugs, Antineoplastic
- Antineoplastics
- Chemotherapeutic Anticancer Drug
- Drug, Chemotherapeutic Anticancer
- Antitumor Drugs
- Drugs, Antitumor
- Cancer Chemotherapy Agents
- Agents, Cancer Chemotherapy
- Chemotherapy Agents, Cancer
- Cancer Chemotherapy Drugs
- Chemotherapy Drugs, Cancer
- Drugs, Cancer Chemotherapy
- Chemotherapeutic Anticancer Agents
- Agents, Chemotherapeutic Anticancer
- Anticancer Agents
- Agents, Anticancer
- Antitumor Agents
- Agents, Antitumor
|
Below are MeSH descriptors whose meaning is more general than "Antineoplastic Agents".
Below are MeSH descriptors whose meaning is more specific than "Antineoplastic Agents".
This graph shows the total number of publications written about "Antineoplastic Agents" by people in this website by year, and whether "Antineoplastic Agents" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
1982 | 1 | 1 | 2 | 1983 | 1 | 0 | 1 | 1986 | 3 | 2 | 5 | 1987 | 1 | 0 | 1 | 1989 | 1 | 0 | 1 | 1990 | 3 | 1 | 4 | 1992 | 2 | 0 | 2 | 1994 | 1 | 1 | 2 | 1995 | 2 | 5 | 7 | 1997 | 1 | 0 | 1 | 1998 | 4 | 1 | 5 | 1999 | 2 | 1 | 3 | 2000 | 3 | 1 | 4 | 2001 | 4 | 3 | 7 | 2002 | 3 | 3 | 6 | 2003 | 6 | 2 | 8 | 2004 | 9 | 2 | 11 | 2005 | 5 | 2 | 7 | 2006 | 5 | 4 | 9 | 2007 | 10 | 3 | 13 | 2008 | 6 | 1 | 7 | 2009 | 7 | 3 | 10 | 2010 | 8 | 3 | 11 | 2011 | 4 | 3 | 7 | 2012 | 8 | 2 | 10 | 2013 | 13 | 1 | 14 | 2014 | 6 | 2 | 8 | 2015 | 8 | 0 | 8 | 2016 | 5 | 9 | 14 | 2017 | 3 | 3 | 6 | 2018 | 5 | 4 | 9 | 2019 | 5 | 1 | 6 | 2020 | 4 | 1 | 5 | 2021 | 7 | 4 | 11 | 2022 | 3 | 0 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Antineoplastic Agents" by people in Profiles.
-
Boni V, Fidler MJ, Arkenau HT, Spira A, Meric-Bernstam F, Uboha N, Sanborn RE, Sweis RF, LoRusso P, Nagasaka M, Garcia-Corbacho J, Jalal S, Harding JJ, Kim SK, Miedema IHC, Vugts DJ, Huisman MC, Zwezerijnen GJC, van Dongen GAMS, Menke van der Houven van Oordt CW, Wang S, Dang T, Zein IA, Vasiljeva O, Lyman SK, Paton V, Hannah A, Liu JF. Praluzatamab Ravtansine, a CD166-Targeting Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial. Clin Cancer Res. 2022 05 13; 28(10):2020-2029.
-
Vincenzi B, Napolitano A, Fiocco M, Mir O, Rutkowski P, Blay JY, Reichardt P, Joensuu H, Fumagalli E, Gennatas S, Hindi N, Nannini M, Spalato Ceruso M, Italiano A, Grignani G, Brunello A, Gasperoni S, De Pas T, Badalamenti G, Pantaleo MA, van Houdt WJ, IJzerman NS, Steeghs N, Gelderblom H, Desar IME, Falkenhorst J, Silletta M, Sbaraglia M, Tonini G, Martin-Broto J, Hohenberger P, Le Cesne A, Jones RL, Dei Tos AP, Gronchi A, Bauer S, Casali PG. Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study. Clin Cancer Res. 2022 04 14; 28(8):1672-1679.
-
Napolitano A, Thway K, Smith MJ, Huang PH, Jones RL. KIT Exon 9-Mutated Gastrointestinal Stromal Tumours: Biology and Treatment. Chemotherapy. 2022; 67(2):81-90.
-
Li Z, Xu H, Gong Y, Chen W, Zhan Y, Yu L, Sun Y, Li A, He S, Guan B, Wu Y, Xiong G, Fang D, He Y, Tang Q, Yao L, Hu Z, Mei H, He Z, Cai Z, Guo Y, Li X, Zhou L, Huang W. Patient-Derived Upper Tract Urothelial Carcinoma Organoids as a Platform for Drug Screening. Adv Sci (Weinh). 2022 02; 9(4):e2103999.
-
Kang YK, George S, Jones RL, Rutkowski P, Shen L, Mir O, Patel S, Zhou Y, von Mehren M, Hohenberger P, Villalobos V, Brahmi M, Tap WD, Trent J, Pantaleo MA, Schöffski P, He K, Hew P, Newberry K, Roche M, Heinrich MC, Bauer S. Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study. J Clin Oncol. 2021 10 01; 39(28):3128-3139.
-
Lalazar G, Requena D, Ramos-Espiritu L, Ng D, Bhola PD, de Jong YP, Wang R, Narayan NJC, Shebl B, Levin S, Michailidis E, Kabbani M, Vercauteren KOA, Hurley AM, Farber BA, Hammond WJ, Saltsman JA, Weinberg EM, Glickman JF, Lyons BA, Ellison J, Schadde E, Hertl M, Leiting JL, Truty MJ, Smoot RL, Tierney F, Kato T, Wendel HG, LaQuaglia MP, Rice CM, Letai A, Coffino P, Torbenson MS, Ortiz MV, Simon SM. Identification of Novel Therapeutic Targets for Fibrolamellar Carcinoma Using Patient-Derived Xenografts and Direct-from-Patient Screening. Cancer Discov. 2021 10; 11(10):2544-2563.
-
Smrke A, Benson C, Strauss DC, Hayes AJ, Thway K, Hallin M, Fisher C, Messiou C, Huang PH, Jones RL, Smith MJ. Gastrointestinal leiomyosarcoma demonstrate a predilection for distant recurrence and poor response to systemic treatments. Eur J Surg Oncol. 2021 10; 47(10):2595-2601.
-
Lehrich BM, Abiri A, Goshtasbi K, Birkenbeuel J, Yasaka TM, Papagiannopoulos P, Tajudeen BA, Brem EA, Kuan EC. Treatment Modalities and Survival Outcomes for Sinonasal Diffuse Large B-Cell Lymphoma. Laryngoscope. 2021 11; 131(11):E2727-E2735.
-
Chamberlain F, Benson C, Thway K, Huang P, Jones RL, Gennatas S. Pharmacotherapy for liposarcoma: current and emerging synthetic treatments. Future Oncol. 2021 Jul; 17(20):2659-2670.
-
Mohammadi M, IJzerman NS, Hohenberger P, Rutkowski P, Jones RL, Martin-Broto J, Gronchi A, Schöffski P, Vassos N, Farag S, Baia M, Oosten AW, Steeghs N, Desar IME, Reyners AKL, van Sandick JW, Bastiaannet E, Gelderblom H, Schrage Y. Clinicopathological features and treatment outcome of oesophageal gastrointestinal stromal tumour (GIST): A large, retrospective multicenter European study. Eur J Surg Oncol. 2021 08; 47(8):2173-2181.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|